BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 29070066)

  • 1. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
    Ritchie CW; Russ TC; Banerjee S; Barber B; Boaden A; Fox NC; Holmes C; Isaacs JD; Leroi I; Lovestone S; Norton M; O'Brien J; Pearson J; Perry R; Pickett J; Waldman AD; Wong WL; Rossor MN; Burns A
    Alzheimers Res Ther; 2017 Oct; 9(1):85. PubMed ID: 29070066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.
    Small GW; Rabins PV; Barry PP; Buckholtz NS; DeKosky ST; Ferris SH; Finkel SI; Gwyther LP; Khachaturian ZS; Lebowitz BD; McRae TD; Morris JC; Oakley F; Schneider LS; Streim JE; Sunderland T; Teri LA; Tune LE
    JAMA; 1997 Oct 22-29; 278(16):1363-71. PubMed ID: 9343469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Italian INTERCEPTOR Project: From the Early Identification of Patients Eligible for Prescription of Antidementia Drugs to a Nationwide Organizational Model for Early Alzheimer's Disease Diagnosis.
    Rossini PM; Cappa SF; Lattanzio F; Perani D; Spadin P; Tagliavini F; Vanacore N
    J Alzheimers Dis; 2019; 72(2):373-388. PubMed ID: 31594234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome.
    Caraci F; Iulita MF; Pentz R; Flores Aguilar L; Orciani C; Barone C; Romano C; Drago F; Cuello AC
    Eur J Pharmacol; 2017 Dec; 817():7-19. PubMed ID: 28987272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Leuzy A; Heurling K; Ashton NJ; Schöll M; Zimmer ER
    Yale J Biol Med; 2018 Sep; 91(3):291-300. PubMed ID: 30258316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK.
    Laurell AAS; Venkataraman AV; Schmidt T; Montagnese M; Mueller C; Stewart R; Lewis J; Mundell C; Isaacs JD; Krishnan MS; Barber R; Rittman T; Underwood BR
    Br J Psychiatry; 2024 Jun; 224(6):198-204. PubMed ID: 38235531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Amyloid Therapies for Alzheimer's Disease: An Alzheimer Europe Position Paper and Call to Action.
    Bradshaw AC; Georges J
    J Prev Alzheimers Dis; 2024; 11(2):265-273. PubMed ID: 38374732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years.
    Epelbaum S; Paquet C; Hugon J; Dumurgier J; Wallon D; Hannequin D; Jonveaux T; Besozzi A; Pouponneau S; Hommet C; Blanc F; Berly L; Julian A; Paccalin M; Pasquier F; Bellet J; Boutoleau-Bretonniere C; Charriau T; Rouaud O; Madec O; Mouton A; David R; Bekadar S; Fabre R; Liegey E; Deberdt W; Robert P; Dubois B
    BMJ Open; 2019 Jun; 9(6):e029663. PubMed ID: 31239309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissonance in the face of Alzheimer's disease breakthroughs: clinician and lay stakeholder acceptance, concerns and willingness to pay for emerging disease-modifying therapies.
    Kinchin I; Walsh S; Dinh R; Kapuwa M; Kennelly SP; Miller AM; Nolan A; O'Dowd S; O'Philbin L; Timmons S; Leroi I
    Br J Psychiatry; 2024 Jun; 224(6):230-236. PubMed ID: 38629297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease.
    Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
    Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside.
    Pawlowski M; Meuth SG; Duning T
    Diagnostics (Basel); 2017 Jul; 7(3):. PubMed ID: 28703785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.